These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8190659)

  • 1. [Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
    Polakowska M; Broda G; Rywik S; Piotrowski W; Bednarska M; Kuźmińska A; Pytlak A; Chotkowska E
    Pol Arch Med Wewn; 1994 Jan; 91(1):9-18. PubMed ID: 8190659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
    Sirtori CR; Franceschini G; Gianfranceschi G; Vaccarino V; Chiesa G; Maderna P; Bertoli M; Calabresi L
    Eur J Epidemiol; 1992 May; 8 Suppl 1():120-4. PubMed ID: 1505648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
    Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
    Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gemfibrozil on serum lipid levels.
    Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
    Artery; 1980; 7(3):224-31. PubMed ID: 7008748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia].
    Julius U; Hora C; Gross P; Fücker K; Bergmann S; Hanefeld M
    Fortschr Med; 1992 Dec; 110(35-36):669-72. PubMed ID: 1487226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 15. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia.
    Avellone G; Di Garbo V; Panno AV; Cordova R; Lepore R; Strano A
    Int Angiol; 1988; 7(3):270-7. PubMed ID: 3198979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia].
    Manojlović D; Lepsanović L; Micić D; Sumarac M; Kendereski L; Popović V; Mićić J
    Srp Arh Celok Lek; 1991; 119(1-2):22-5. PubMed ID: 1788614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
    Corder CN; Kloer HU; Price MD
    Eur J Clin Pharmacol; 1989; 37(5):477-81. PubMed ID: 2598985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
    Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.